StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
66
This month
2
This week
1
This year
4
Today
1
Yesterday
1
Publishing Date
2024 - 03 - 26
1
2023 - 12 - 11
1
2023 - 11 - 10
1
2023 - 11 - 01
1
2023 - 10 - 25
1
2023 - 10 - 16
1
2023 - 09 - 20
1
2023 - 08 - 24
1
2023 - 07 - 26
1
2023 - 07 - 21
1
2023 - 06 - 16
1
2023 - 06 - 08
1
2023 - 06 - 01
1
2023 - 05 - 15
1
2023 - 04 - 13
1
2023 - 03 - 10
1
2023 - 03 - 02
1
2023 - 02 - 22
1
2022 - 12 - 22
1
2022 - 12 - 21
1
2022 - 12 - 20
2
2022 - 12 - 15
1
2022 - 10 - 12
1
2022 - 10 - 10
1
2022 - 09 - 22
1
2022 - 09 - 20
1
2022 - 09 - 13
1
2022 - 08 - 04
1
2022 - 07 - 13
1
2022 - 06 - 27
1
2022 - 06 - 24
1
2022 - 05 - 24
1
2022 - 04 - 18
1
2022 - 04 - 01
1
2022 - 03 - 31
1
2021 - 12 - 24
1
2021 - 11 - 30
2
2021 - 11 - 29
1
2021 - 11 - 23
1
2021 - 11 - 03
1
2021 - 10 - 27
1
2021 - 10 - 26
1
2021 - 10 - 25
2
2021 - 10 - 22
1
2021 - 10 - 11
1
2021 - 09 - 07
1
2021 - 08 - 31
1
2021 - 06 - 24
1
2021 - 06 - 17
1
2021 - 06 - 09
1
2021 - 06 - 07
1
2021 - 05 - 24
1
2021 - 05 - 05
1
2021 - 04 - 27
1
2021 - 03 - 23
1
2021 - 03 - 15
1
2021 - 03 - 08
1
2021 - 01 - 26
1
2020 - 12 - 23
1
2020 - 12 - 11
1
Sector
Communications
12
Health technology
66
Manufacturing
2
Tags
Alliances
8
Antiviral
5
Application
4
Approved
4
Biocanada
4
Breast cancer
4
Canada
4
Cancer
31
Cell
5
Cell carcinoma
3
China
3
Chmp
5
Clinical-trials-phase-iii
5
Collaboration
2
Colorectal cancer
3
Commercialization
2
Covid
7
Europe
3
Events
2
Fda
13
Fda approval
3
Fda-approvals
4
Gemcitabine
2
Health
4
Her2
5
Her2+
2
Her2-
5
Hiv
6
Hypertension
2
Infection
2
Keytruda
33
License
4
Lung
4
Lynparza
8
Melanoma
3
Merck
6
Merge
2
Molnupiravir
7
N/a
3
Padcev
2
Pharm-country
6
Pharmaceutical
12
Phase 2
2
Phase 3
2
Plus
12
Positive
8
Product-news
2
Prostate cancer
4
Regulatory
11
Renal
4
Research
7
Review
3
Risk
5
Rna-4157
2
Study
2
Submission
2
Therapy
8
Treatment
63
Trial
5
Trials
2
Entities
3m company
21
Abbott laboratories
61
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
209
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
66
Moleculin biotech, inc.
28
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
22
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
295
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
54
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
ALPMF
2
ALPMY
2
ARAY
1
AZN
1
AZNCF
1
CLVS
1
DARE
1
FNCTF
12
GILD
2
JNJ
2
MRK
66
MRNA
2
ONCY
1
SGEN
2
Exchanges
Nasdaq
20
Nyse
66
Crawled Date
2024 - 03 - 26
1
2023 - 12 - 11
1
2023 - 11 - 10
1
2023 - 11 - 01
1
2023 - 10 - 25
1
2023 - 10 - 16
1
2023 - 09 - 20
1
2023 - 08 - 24
1
2023 - 07 - 26
1
2023 - 07 - 21
1
2023 - 06 - 16
1
2023 - 06 - 08
1
2023 - 06 - 01
1
2023 - 05 - 15
1
2023 - 04 - 13
1
2023 - 03 - 10
1
2023 - 03 - 02
1
2023 - 02 - 22
1
2022 - 12 - 22
1
2022 - 12 - 21
1
2022 - 12 - 20
2
2022 - 12 - 15
1
2022 - 10 - 12
1
2022 - 10 - 10
1
2022 - 09 - 22
1
2022 - 09 - 20
1
2022 - 09 - 13
1
2022 - 08 - 04
1
2022 - 07 - 13
1
2022 - 06 - 27
1
2022 - 06 - 24
1
2022 - 05 - 24
1
2022 - 04 - 18
1
2022 - 04 - 01
1
2022 - 03 - 31
1
2021 - 12 - 24
1
2021 - 11 - 30
2
2021 - 11 - 29
1
2021 - 11 - 23
1
2021 - 11 - 03
1
2021 - 10 - 27
1
2021 - 10 - 26
1
2021 - 10 - 25
2
2021 - 10 - 22
1
2021 - 10 - 11
1
2021 - 09 - 07
1
2021 - 08 - 31
1
2021 - 06 - 24
1
2021 - 06 - 17
1
2021 - 06 - 09
1
2021 - 06 - 07
1
2021 - 05 - 24
1
2021 - 05 - 06
1
2021 - 04 - 27
1
2021 - 03 - 23
1
2021 - 03 - 15
1
2021 - 03 - 09
1
2021 - 01 - 26
1
2020 - 12 - 23
1
2020 - 12 - 11
1
Crawled Time
01:00
2
11:00
13
12:00
27
12:20
4
12:30
3
13:00
4
13:20
1
13:30
1
14:00
2
14:30
1
15:00
2
16:00
1
18:00
2
19:00
1
21:00
1
23:00
1
Source
www.biospace.com
63
www.prnewswire.com
3
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Merck & company, inc.
save search
Health Canada Approves KEYTRUDA as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma
Published:
2024-04-19
(Crawled : 13:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
0.33%
|
O:
0.22%
H:
0.37%
C:
0.1%
health
treatment
for
canada
advanced
keytruda
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published:
2024-04-04
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
-3.63%
|
O:
0.24%
H:
0.08%
C:
-2.42%
mk-1084
keytruda
lung
merck
cancer
cell
treatment
trial
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published:
2024-03-28
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
-4.53%
|
O:
0.18%
H:
0.0%
C:
0.0%
keytruda
lung
cancer
cell
risk
plus
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published:
2024-03-26
(Crawled : 23:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
0.38%
|
O:
0.38%
H:
0.24%
C:
-0.21%
fda
group
treatment
hypertension
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
Published:
2023-12-11
(Crawled : 14:30)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
21.23%
|
O:
1.06%
H:
0.59%
C:
-0.46%
MRNA
S
|
$101.44
-0.55%
-0.55%
2.6M
|
Health Technology
|
26.26%
|
O:
-0.47%
H:
3.28%
C:
2.58%
rna-4157
keytruda
lung
merck
cancer
cell
treatment
study
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published:
2023-11-10
(Crawled : 14:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
22.86%
|
O:
0.45%
H:
0.51%
C:
-1.41%
keytruda
chmp
merck
positive
cancer
treatment
plus
gemcitabine
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Published:
2023-11-01
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
22.47%
|
O:
0.83%
H:
0.66%
C:
-0.68%
keytruda
fda
cancer
treatment
plus
gemcitabine
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Published:
2023-10-25
(Crawled : 12:30)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
22.08%
|
O:
0.31%
H:
1.22%
C:
0.27%
renal
cell
treatment
lenvima
plus
keytruda
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Published:
2023-10-16
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
20.93%
|
O:
0.18%
H:
1.12%
C:
-0.06%
keytruda
lung
cancer
cell
treatment
risk
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published:
2023-09-20
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
17.16%
|
O:
0.79%
H:
0.18%
C:
-0.83%
keytruda
fda
review
cancer
treatment
application
grants
plus
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published:
2023-08-24
(Crawled : 12:00)
- biospace.com/
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
0.5%
|
O:
1.28%
H:
0.0%
C:
0.0%
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
13.01%
|
O:
-0.31%
H:
0.96%
C:
-1.35%
lynparza
japan
approved
cancer
treatment
plus
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Published:
2023-07-26
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
16.97%
|
O:
-0.68%
H:
1.13%
C:
0.32%
MRNA
S
|
$101.44
-0.55%
-0.55%
2.6M
|
Health Technology
|
-16.79%
|
O:
0.0%
H:
0.07%
C:
-1.0%
rna-4157
keytruda
melanoma
merck
treatment
study
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction
Published:
2023-07-21
(Crawled : 13:20)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
15.97%
|
O:
0.25%
H:
1.73%
C:
1.53%
keytruda
chmp
merck
positive
treatment
plus
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published:
2023-06-16
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
14.97%
|
O:
0.09%
H:
0.87%
C:
-0.16%
keytruda
treatment
plus
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
Published:
2023-06-08
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
15.81%
|
O:
-0.28%
H:
2.55%
C:
1.86%
keytruda
fda
cancer
treatment
application
plus
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published:
2023-06-01
(Crawled : 12:20)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
13.92%
|
O:
0.23%
H:
0.84%
C:
0.24%
lynparza
fda
cancer
treatment
plus
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
Published:
2023-05-15
(Crawled : 12:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
7.38%
|
O:
0.0%
H:
0.51%
C:
-0.66%
merck
asco
pipeline
treatment
research
meeting
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published:
2023-04-13
(Crawled : 11:00)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
10.58%
|
O:
1.07%
H:
0.74%
C:
0.53%
keytruda
fda
treatment
application
plus
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Published:
2023-03-10
(Crawled : 12:20)
- biospace.com/
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
16.9%
|
O:
-0.15%
H:
3.05%
C:
0.23%
keytruda
treatment
plus
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published:
2023-03-02
(Crawled : 16:00)
- biospace.com/
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
-2.34%
|
O:
1.68%
H:
0.0%
C:
0.0%
MRK
|
News
|
$125.78
0.44%
0.0%
8.4M
|
Health Technology
|
17.94%
|
O:
-0.02%
H:
0.7%
C:
0.36%
lynparza
treatment
review
update
cancer
← Previous
1
2
3
4
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
AGBA
|
News
|
$1.26
215.0%
68.25%
130M
|
Finance
EGOX
|
$0.0515
43.06%
30.1%
330M
|
OLB
4
|
$0.33
-14.95%
25.53%
840K
|
Technology Services
NVFY
|
$2.77
31.28%
23.83%
33M
|
Consumer Durables
ZCMD
|
$1.87
28.97%
22.46%
31M
|
Commercial Services
RCON
|
$0.1112
13.01%
21.28%
1.7M
|
Distribution Services
INSG
|
$3.03
25.21%
20.13%
330K
|
Electronic Technology
GCTK
|
$0.8191
22.25%
18.2%
190K
|
Manufacturing
WLGS
|
$0.59
18.0%
17.9%
2.3M
|
ASNS
|
$0.828
21.75%
17.86%
18K
|
Your saved searches
Save your searches and get alerts when important news are released.